CooperVision Targets High-Growth Daily Lens Market With Sauflon Buy
This article was originally published in The Gray Sheet
The $1.2 billion acquisition of Sauflon Pharmaceuticals will increase Cooper’s penetration in the high-growth daily disposable silicone hydrogel contact lens market.
You may also be interested in...
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.
Loss of exclusivity and other competitive pressures will continue to offset J&J’s pharmaceutical growth as its former blockbusters accumulate in ex-growth "other" categories. Can the pipeline take up the slack?
Roche remains the European sector’s biggest company despite a wobble in 2022, but Novo Nordisk’s spectacular growth has seen it overtake AstraZeneca and Novartis in market cap terms.